Use of specifically engineered enzymes to enhance the efficacy of prodrugs
US8349318B2 · kind B2 · utility
0Cited by
3References
67Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 18, 2009 |
| Grant date | Jan 8, 2013 |
| Priority date | — |
| Expiry date | Oct 14, 2029 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides methods for enhancing efficiency of prodrugs by specifically engineered enzymes with altered or enhanced activity and broader substrate specificity towards nucleoside analogs used in cancer chemotherapy, and delivering the enzymes to specific target cells in a patient. The invention also provides modified deoxycytidine kinase (dCK) mutants with such enhanced activities. Furthermore, the invention provides antibody-conjugated enzymes, pharmaceutical composition and kit containing the same, that can be specifically delivered to tumor cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.